Stock image of Covid-19 jab
(Picture: PA Wire)A Covid-19 vaccine that showed it is 100 per cent effective in preventing severe disease and hospitalisation in its trial data is seeking regulatory approval.
French-owned Sanofi and British partner GlaxoSmithKline have manufactured the jab which they hope can be used both as a booster and standalone two-dose shot.
The companies said early data from the late-stage trial indicates it showed it was 100 per cent effecting in preventing severe disease and hospitalisation, with 75 per cent efficacy against moderate or severe disease.
Now they are seeking regulatory approval and will submit data from a late stage trial of the vaccine.
Sanofi and GSK are also testing their formula as a booster with full results for both studies due to released “later this year”.
Final analysis of the booster trial showed the Sanofi-GSK jab could increase neutralising bodies by 18 to 30 times, the companies said.
Sanofi plans to make the vaccine in France, Italy and the US.
Both companies are behind competitors in producing a Covid-19 vaccine, with GSK not developing its own but contributing its adjuvant technology to developments.
The Sanofi-GSK’s jab relies on a conventional protein-based approach.
This compares with newer mRNA technology found in vaccines such as the Pfizer-BioNTech and Moderna jabs.
“We are confident that this vaccine can play an important role as we continue to address this pandemic and prepare for the post-pandemic period,” said president of GSK vaccines Roger Connor.
“No other global Phase 3 efficacy study has been undertaken during this period with so many variants of concern, including Omicron, and these efficacy data are similar to the recent clinical data from authorised vaccines,” said Thomas Triomphe, executive vice president for Sanofi Vaccines.
